{"article_title": "Following Pending Adheron Deal, Roche Buys Healthcare Ventures-Backed Tensha Therapeutics", "article_keywords": ["adheron", "roche", "product", "therapeutics", "deal", "purchase", "company", "buys", "venturesbacked", "ten010", "tensha", "shire", "healthcare", "following", "pending", "million"], "article_url": "http://www.themiddlemarket.com/news/healthcare/following-pending-adheron-deal-roche-buys--259591-1.html", "article_text": "Following Pending Adheron Deal, Roche Buys Healthcare Ventures-Backed Tensha Therapeutics\n\nThe buyer is adding the biotech company, known for its Ten-010 product, after Shire agreed to purchase Baxalta and Dyax\n\nRoche Holding AG (VTX: ROG) has agreed to purchase venture capital-backed biotechnology company Tensha Therapeutics for up to $535 million.\n\nThe deal calls for Roche to pay $115 million in upfront cash and up to another $420 million that is based on the target\u2019s future performance\n\nTensha has developed a biotechnology product, called Ten-010, that is designed to potentially treat cancer patients and it is currently in clinical trials. Tensha is backed by Healthcare Ventures. Tensha CEO Douglas Onsi says \u201cRoche is the ideal company to explore the broad clinical potential of Ten-010.\u201d\n\nIn 2015, Roche announced plans to buy Adheron Therapeutics. In other similar deals, Charles River is planning on buying Wil Research and Shire plc (LON: SHP) is adding Dyax Corp along with Baxalta.\n\nFor more information on related topics, visit the following:", "article_metadata": {"og": {"url": "http://www.themiddlemarket.com/news/healthcare/following-pending-adheron-deal-roche-buys--259591-1.html", "image": "http://cdn.themiddlemarket.com/media/newspics/biotech.jpeg", "site_name": "Mergers & Acquisitions, Latest News", "title": "Following Pending Adheron Deal, Roche Buys Healthcare Ventures-Backed Tensha Therapeutics"}}, "article_summary": "Following Pending Adheron Deal, Roche Buys Healthcare Ventures-Backed Tensha TherapeuticsThe buyer is adding the biotech company, known for its Ten-010 product, after Shire agreed to purchase Baxalta and DyaxRoche Holding AG (VTX: ROG) has agreed to purchase venture capital-backed biotechnology company Tensha Therapeutics for up to $535 million.\nTensha CEO Douglas Onsi says \u201cRoche is the ideal company to explore the broad clinical potential of Ten-010.\u201dIn 2015, Roche announced plans to buy Adheron Therapeutics.\nTensha is backed by Healthcare Ventures.\nIn other similar deals, Charles River is planning on buying Wil Research and Shire plc (LON: SHP) is adding Dyax Corp along with Baxalta.\nFor more information on related topics, visit the following:"}